AZN vs LLY
AstraZeneca PLC and Eli Lilly, both Healthcare
Eli Lilly is the larger company at $1.2T against $266B. Over the past year LLY returned +56% against +3.4% for AZN. The RyuScore puts AZN ahead, 62 against 60 out of 100.
| Figure | AZN | LLY |
|---|---|---|
| Last close | $171 | $1274 |
| Market cap | $266B | $1.2T |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 42.8 |
| Dividend yield | n/a | 0.5% |
| 1-year return | +3.4% | +56% |
| 5-year return | +55% | +470% |
| RyuScoresector-relative, 1–10 | 62/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Eli Lilly
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.